-
1.发明公开
公开(公告)号：EP3626730A1
公开(公告)日：2020-03-25
申请号：EP19199106.6
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
-
2.发明公开
公开(公告)号：EP3626731A1
公开(公告)日：2020-03-25
申请号：EP19199125.6
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
-
3.发明公开
公开(公告)号：EP3236985A1
公开(公告)日：2017-11-01
申请号：EP15813809.9
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , KUTSCHER, Sarah
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C07K2317/70 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
摘要翻译： 本发明涉及用于免疫治疗方法的肽，蛋白质，核酸和细胞。 具体而言，本发明涉及癌症的免疫治疗。 本发明还涉及单独或与其他肿瘤相关肽组合的肿瘤相关T细胞肽表位，其可以例如用作刺激抗肿瘤免疫应答或刺激T细胞的疫苗组合物的活性药物成分 离体和转移入患者。 与主要组织相容性复合物（MHC）的分子结合的肽或肽本身也可以是抗体，可溶性T细胞受体和其他结合分子的靶标。 具体而言，本发明涉及几种新的肽序列及其衍生自人肿瘤细胞的HLA I类和II类分子的变体，其可用于引发抗肿瘤免疫应答的疫苗组合物或作为药物开发的靶 /免疫活性化合物和细胞。
-
4.发明公开
公开(公告)号：EP3715357A1
公开(公告)日：2020-09-30
申请号：EP20172206.3
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
摘要： The current invention relates to a pharmaceutical composition comprising a peptide of the sequence according to SEQ ID No. 303 together with at least one suitable carrier and/or excipient for use in the treatment of Hepatocellular carcinoma cancer (HCC).
-
5.发明公开
公开(公告)号：EP3626729A1
公开(公告)日：2020-03-25
申请号：EP19199101.7
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
-
6.发明公开
公开(公告)号：EP4461371A2
公开(公告)日：2024-11-13
申请号：EP24199595.0
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
IPC分类号： A61P35/00
摘要： The current invention relates to a peptide comprising the sequence of SEQ ID NO: 5, a binding molecule specifically binding to the peptide, a nucleic acid encoding the peptide or the binding molecule, a host cell comprising the nucleic acid and the use of the peptide, the binding molecule, the nucleic acid or the host cell in medicine, in particular in the treatment of cancer.
-
7.发明公开
公开(公告)号：EP3620168A1
公开(公告)日：2020-03-11
申请号：EP19199114.0
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
-
8.发明公开
公开(公告)号：EP3616706A1
公开(公告)日：2020-03-04
申请号：EP19199098.5
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
-
9.发明公开
公开(公告)号：EP3331900A2
公开(公告)日：2018-06-13
申请号：EP16750766.4
申请日：2016-08-05
发明人： MAHR, Andrea , WEINSCHENK, Toni , SCHOOR, Oliver , FRITSCHE, Jens , SINGH, Harpreet , MÜLLER, Phillip , LEIBOLD, Julia , GOLDFINGER, Valentina
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C07K2319/00 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N33/5748 , G01N33/6848 , G01N2570/00 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.04 秒)
